MISONIX INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2021 12 months to Jun 30, 2021	FY2020 12 months to Jun 30, 2020	FY2019 12 months to Jun 30, 2019	FY2018 12 months to Jun 30, 2018	FY2017 12 months to Jun 30, 2017
Net (loss)/income from continuing operations
Net loss
Net income from discontinued operations
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
Depreciation and amortization
Deferred income tax expense
Rent expense from operating lease right-of-use asset
Bad debt expense
Reserve for contract asset
Stock-based compensation
Deferred income
Deferred lease liability
Deferred lease liability and income
Stock bonus
Release of valuation allowance on deferred tax assets
Changes in operating assets and liabilities:
Accounts receivable
Inventories
Prepaid expenses and other current assets
Other assets
Operating leases and other assets
Accounts payable, accrued expenses and other
Net cash used in operating activities
Deferred tax liabilities

Net cash used in operating activities
Investing activities
Acquisition of property, plant and equipment
Additional patents
Net cash used in investing continuing activities
Net cash provided by investing activities - discontinued operations
Net cash provided by discontinued operations
Cash from acquisition of Solsys Medical, LLC
Net cash (used in) provided by investing activities

Financing activities
Proceeds from sale of common stock
Proceeds from notes payable
Repayments of notes payable
Proceeds from exercise of stock options
Net cash provided by financing activities

Net decrease in cash and cash equivalents
Stock registration and investment bank fees
Proceeds from equity offering
Payments of finance lease
Payments for fractional shares released from escrow
Net cash provided by financing activities
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at the beginning of the period
Cash and cash equivalents at the end of the period
Supplemental disclosure of cash flow information:
Cash paid for:
Interest
Income taxes
Transfer of inventory to property, plant and equipment for consignment of product
Adoption of new accounting standard on deferred taxes
Accrued but unpaid costs to register equity for acquisition

Transfer of inventory to property, plant and equipment for consignment of product
Right-of-use assets obtained in exchange for new operating lease liabilities
Accrued but unpaid costs to register equity for acquisition
Stock issued for the acquisition of Solsys Medical, LLC
Shares release from escrow

Comments